<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H83A5A645A4114251BB71454BCA64089E" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 HR 5729 IH: Adding Ebola to the FDA Priority Review Voucher Program Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2014-11-18</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>2d Session</session>
		<legis-num>H. R. 5729</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20141118">November 18, 2014</action-date>
			<action-desc><sponsor name-id="B001243">Mrs. Blackburn</sponsor> (for herself, <cosponsor name-id="G000410">Mr. Gene Green of Texas</cosponsor>, <cosponsor name-id="B001251">Mr. Butterfield</cosponsor>, <cosponsor name-id="M001157">Mr. McCaul</cosponsor>, and <cosponsor name-id="F000459">Mr. Fleischmann</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To expand the program of priority review to encourage treatments for tropical diseases.</official-title>
	</form>
	<legis-body id="HA1A97D5DCDC14BCC9262117C7A5D2AF5" style="OLC">
		<section id="H39D3C0A6535842F4A8A89E736E9A418C" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Adding Ebola to the FDA Priority Review Voucher Program Act</short-title></quote>.</text>
		</section><section id="H1CD61A4E39284BC99B0EE669AE1DC345" section-type="subsequent-section"><enum>2.</enum><header>Priority review to encourage treatments for tropical diseases</header><text display-inline="no-display-inline">Section 524 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360n">21 U.S.C. 360n</external-xref>) is amended—</text>
			<paragraph id="H08CCEF36EE704B25A1CB45B31F5CB4EE"><enum>(1)</enum><text>in subsection (a)(3)—</text>
				<subparagraph id="H01D79E5E527646BA9146EBFBA9707AAE"><enum>(A)</enum><text>by redesignating subparagraph (Q) as subparagraph (R);</text>
				</subparagraph><subparagraph id="HAF65F12CA5DF461D9A189B9A948F0DF3"><enum>(B)</enum><text>by inserting after subparagraph (P) the following:</text>
					<quoted-block display-inline="no-display-inline" id="HD2EB684FB41746BD9B6F3E9E68B218F7" style="OLC">
						<subparagraph id="H533C2007E0C74D388DB4AF280B2410A4"><enum>(Q)</enum><text>Filoviruses.</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block>
				</subparagraph><subparagraph id="H2F5EC8D0542B4398953CD6794A856EFB"><enum>(C)</enum><text>in subparagraph (R), as so redesignated, by striking <quote>regulation by</quote> and inserting <quote>order of</quote>; and</text>
				</subparagraph></paragraph><paragraph id="HB36358164A0F4E28B3EA729CFEF44D7F"><enum>(2)</enum><text>in subsection (b)—</text>
				<subparagraph id="HCFC3147A598B41A3BDEEB90CD94CDB2A"><enum>(A)</enum><text>in paragraph (2), by adding <quote>There is no limit on the number of times a priority review voucher may be transferred before such
			 voucher is used.</quote> after the period at the end; and</text>
				</subparagraph><subparagraph id="H57973A1F624347CF87FA3A4EB8AE3319"><enum>(B)</enum><text>in paragraph (4), by striking <quote>365 days</quote> and inserting <quote>90 days</quote>.</text>
				</subparagraph></paragraph></section></legis-body>
</bill>


